Rasio cepet: Kamada Ltd. (KMDA)

Kamada Ltd. (KMDA) maintains stability regardless of market volatility due to constant demand for specialized medications, as confirmed by the price trajectory shown below. The business relies on an impeccable reputation for creating safe plasma-derived products. The liquidity ratio is 2.38. Current success is based on raw material availability, distribution efficiency in the US, and progress in the therapy of rare pathologies.

The quick ratio measures a company's ability to settle short-term debts using cash and accounts receivable, completely excluding illiquid inventories. By analyzing the efficiency of covering current liabilities, an investor can see how the production of rare biologics impacts capital turnover. The specifics of orphan drugs and strict raw material controls minimize dumping risks, stabilizing financial resilience. This approach confirms the reliability of the Kamada Ltd. (KMDA) business model during periods of market volatility.